Qianfeng Xiong

Qianfeng Xiong

Auto-generated profile, based on publicly available information

Qianfeng Xiong

Department of Cardiology, Fengcheng People's Hospital The Affiliated Fengcheng Hospital of Yichun University Fengcheng Jiangxi province China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Closed access
SFShaohua Fan
Shaohua Fan
QXQianfeng Xiong
Qianfeng Xiong
XZXin Zhang
Xin Zhang
LZLihui Zhang
Lihui Zhang
YSYawei Shi
Yawei Shi
Myocardial hypertrophy is a major pathological and physiological process during heart failure. Glucagon-like peptide 1 (GLP-1) is a glucagon incretin hormone released from the gut endocrine L-cells that has protective effects on various cardiovascular diseases, including hypertension, atherosclerosis, and myocardial hypertrophy. However, the protective mechanisms of GLP-1 in myocardial hypertrophy remain unclear. Here, we showed that the GLP-1 agonist liraglutide and dipeptidyl peptidase 4 inhibitor alogliptin decreased heart weight and cardiac muscle cell volume in spontaneously hypertensive rats (SHR). In H9C2 cell hypertensive models induced by angiotensin II, GLP-1 treatment reduced myocardial cell volume, inhibited the expressions of atrial natriuretic peptide, brain/B-type natriuretic peptide, β-myosin heavy chain, RhoA, and ROCK2, and decreased MLC and MYPT1 phosphorylation. When H9C2 cells were treated with H89, a PKA inhibitor, the inhibitory effect of GLP-1 disappeared, while the inhibitory role was enhanced under the treatment of Y-27632, a ROCK2 inhibitor. These results suggested that GLP-1 might reverse myocardial hypertrophy through the PKA/RhoA/ROCK2 signaling pathway.

23 October 2019 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
QXQian-Feng Xiong
Qian-Feng Xiong
SFShao-Hua Fan
Shao-Hua Fan
XLXuewen Li
Xuewen Li
YNYu Niu
Yu Niu
JWJing Wang
Jing Wang
LZLihui Zhang
Lihui Zhang
GLP-1 is a new type of antidiabetic agent that possesses many beneficial effects. Although its cardiovascular actions have been widely examined, little is known about GLP-1’s effects on the rat coronary artery (RCA) or about the mechanisms underpinning these effects. Here, we report that GLP-1 inhibits depolarization- or thromboxane receptor agonist (U46619)-induced RCA contraction in a dosage-dependent manner. Vasorelaxation was attenuated by denuding the endothelium, L-NAME (nitric oxide synthase inhibitor), and glyburide (KATP channel blocker) but was not affected by indomethacin (cyclooxygenase inhibitor), iberiotoxin [Ca2+-activated K+ channel (KCa) blocker], or 4-aminopyridine (KV channel blocker). Furthermore, GLP-1 increased outward K+ currents by enhancing the KATP channel in rat coronary arterial smooth muscle cells (RCASMCs). These results show that GLP-1 is an endothelial-dependent vasospasmolytic agent in the RCA and imply that the relaxant effect is regulated by enhancing KATP rather than KV or KCa currents in RCASMCs.

21 February 2026 in JACC: Case Reports
Verified
Journal Article
Open access
QXQianfeng Xiong
Qianfeng Xiong
YXYaowu Xie
Yaowu Xie
Brugada phenocopy (BrP) denotes reversible Brugada-type electrocardiogram changes from transient triggers, requiring management distinct from congenital Brugada syndrome. A 19-year-old man collapsed at home, regained consciousness in transit, and soon after emergency department arrival had recurrent syncope with ventricular fibrillation, which was defibrillated (200 J). The electrocardiogram showed PR interval approximately 200 milliseconds, QRS interval approximately 160 milliseconds, QTc interval approximately 489 milliseconds, lateral J-waves, and coved ST-segment elevation in V1-V2. A review of his phone confirmed propafenone ingestion (approximately 2.5 g over 3 days). Intravenous sodium bicarbonate led to rapid QRS interval narrowing and clinical stabilization. The triad of diffuse conduction delay, V1-V2 coved morphology, and J-waves in acidemia with dose-verified exposure supports drug-induced BrP. Early bicarbonate reverses sodium-channel blockade; normalization and normal cardiac magnetic resonance argue against a fixed substrate, so implantable cardioverter-defibrillator is unnecessary. BrP resolves after correcting reversible triggers. In sodium-channel blocker toxicity with QRS interval widening, early sodium bicarbonate is first-line therapy.

1 December 2018
Verified
Journal Article
Closed access
QXQian-Feng Xiong
Qian-Feng Xiong
SFShao-Hua Fan
Shao-Hua Fan
XZXin Zhang
Xin Zhang
YNYu Niu
Yu Niu
XLXuewen Li
Xuewen Li
LZLihui Zhang
Lihui Zhang

19 February 2025 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
QXQianfeng Xiong
Qianfeng Xiong
SCShaoyong Chen
Shaoyong Chen
JLJunke Luo
Junke Luo
PXPengfeng Xiong
Pengfeng Xiong
ZNZhenyun Nie
Zhenyun Nie
JWJing Wang
Jing Wang
Background: Elevated homocysteine (Hcy) levels have been linked to poorer outcomes in acute coronary syndrome. This study aimed to assess the predictive value of elevated Hcy levels for major adverse cardiac events (MACE) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Methods: This retrospective cohort study included 183 STEMI patients who underwent primary PCI at a tertiary university hospital in southern China from January 2020 to December 2021. Laboratory values, including Hcy levels, were obtained within 24 hours of admission. Patients were categorized into elevated and normal Hcy groups using a threshold of 12 μmol/L. The study outcome was the occurrence of 6-point MACE, defined as cardiac death, nonfatal myocardial infarction, stroke, ischemia-driven revascularization (PCI or coronary artery bypass grafting), heart failure and all-cause death. Survival analyses were conducted using Kaplan-Meier and Cox proportional hazard methods. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) approaches were employed to minimize bias. Results: The mean age of the patients was 64.8 years, with 76.0% being male. After adjusting with PSM or IPTW, covariate imbalances between the two groups were corrected. Over a median follow-up period of 25.8 months, 55 MACE events occurred, resulting in an event rate of 30.1%. Patients with elevated Hcy levels had a higher incidence of MACE in both unadjusted (hazard ratio [HR] = 2.778; 95% confidence interval [CI]: 1.591–4.850; p < 0.001) and adjusted analyses (PSM: HR = 2.995; 95% CI: 1.397–6.423, p = 0.005; IPTW: HR = 3.2; 95% CI: 1.631–6.280, p < 0.001). Multivariate Cox regression further confirmed that elevated Hcy levels were associated with a worse prognosis across the entire cohort (HR = 1.062, 95% CI: 1.029–1.097, p < 0.001), PSM cohort (HR = 1.089, 95% CI: 1.036–1.145, p < 0.001), and IPTW cohort (HR = 1.052, 95% CI: 1.020–1.086, p = 0.001). Conclusions: Elevated plasma levels of Hcy (≥12 μmol/L) are associated with worse outcomes in STEMI patients undergoing primary PCI, highlighting the potential role of Hcy as a prognostic marker in this population.

7 December 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
QXQianfeng Xiong
Qianfeng Xiong
SCShaoyong Chen
Shaoyong Chen
WZWenhao Zhang
Wenhao Zhang
YXYaowu Xie
Yaowu Xie